#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand package labeling standards to counsel patients on appropriate dosing and help them avoid accidental overconsumption, particularly since potency information directly affects therapeutic outcomes and adverse event risk. As New York City’s legal cannabis market matures, patients increasingly encounter standardized potency labeling that clinicians should be familiar with to provide evidence-based guidance on product selection and safe use.
This article addresses consumer education regarding cannabis product selection in New York City’s regulated market, focusing on understanding total package strength and potency labeling as key metrics for responsible purchasing. Accurate comprehension of cannabinoid concentrations (THC and CBD) across entire products versus per-dose amounts is essential for consumers to make informed choices aligned with their therapeutic or recreational goals and individual tolerance levels. For clinicians, this consumer literacy becomes clinically relevant when patients report cannabis use, as understanding how patients interpret potency and total package amounts directly affects dosing counseling and harm reduction discussions. The ability to quantify and communicate cannabinoid content transparently through labeling standards supports better patient education and safer use patterns. Clinicians should familiarize themselves with how potency is expressed in their local markets and educate patients that higher total package strength does not necessarily correlate with safer or more effective use, particularly in therapeutic applications where precise dosing matters.
“What we’re seeing is a real need for consumers to understand the difference between total package strength and per-serving potency, because that gap is where dosing errors happen in my clinic. The regulatory clarity around labeling in New York is helpful, but patients still need guidance on how their individual metabolism and tolerance will interact with these products, which is why I always recommend starting low and titrating slowly rather than relying on package numbers alone.”
💊 As cannabis retail continues to expand in regulated markets like New York City, patients and providers should recognize that consumer education resources increasingly emphasize potency labeling and total package strength as key decision-making factors. However, individual responses to THC and CBD vary substantially based on genetics, prior exposure, concurrent medications, and route of administration, meaning that potency alone is a poor predictor of clinical outcome or tolerability for any given patient. Providers should be aware that patients may rely on retail guidance rather than medical counsel when selecting products, potentially leading to suboptimal dosing or drug interactions, particularly in older adults or those on CYP3A4-metabolizing medications. The emphasis on “responsible shopping” through potency awareness is a step toward harm reduction, yet it does not address critical gaps such as terpene profiles, individual cannabinoid ratios beyond THC/CBD, or the lack of standardized dosing conventions in the cannabis market.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
